The addition of bevacizumab to a chemotherapy regimen was well tolerated in this elderly population, with only a trend towards significance for hypertension (Table 2 ) in patients treated with bevacizumab; the incidence of all other adverse events was comparable with those receiving chemotherapy alone.
← all excerpts
Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.
1
—
—